Exhibit 32.1
AMPIO PHARMACEUTICALS, INC.
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the filing of the quarterly report on Form 10-Q for the quarter ended June 30, 2023 (the “Report”) by Ampio Pharmaceuticals, Inc. (the “Company”), each of the undersigned hereby certifies:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: August 8, 2023 | /s/ Michael A. Martino |
| Michael A. Martino |
| Chief Executive Officer |
| (principal executive officer) |
|
|
Dated: August 8, 2023 | /s/ Daniel G. Stokely |
| Daniel G. Stokely |
| Chief Financial Officer |
| (principal financial and accounting officer) |
| |